New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export NVAX’s income statement to Excel — free account
Novavax, Inc.
NVAXNovavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024.
- Revenue
- −3.05%
- EPS
- n/m
- Free cash flow
- n/m
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
7.76
0.03
+0.39%
Follow NVAX
Alert me
Revenue to profit Q3 FY2026, quarter to Sep 30, 2026
It lost $31.4M on $68.3M of revenue: $45.94 for every $100. Gross margin has fallen three quarters running, from 85.0% to 65.6%. What is an income statement?
| Revenue | 68.3 | 100.0% |
|---|---|---|
| Cost of revenue | −23.5 | −34.4% |
| Gross profit | 44.8 | 65.6% |
| Research & development | −52.4 | −76.8% |
| Selling, general & admin | −23.6 | −34.6% |
| Operating income | −31.3 | −45.8% |
| Other income, net | +1.6 | 2.4% |
| Income tax | −1.7 | −2.5% |
| Net income | −31.4 | −45.9% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $147M | $140M | $57M | $68M |
| Operating income | $14M | −$15M | −$55M | −$31M |
| Net income | $18M | −$9.5M | −$53M | −$31M |
| Net margin (right axis) | 11.9% | −6.8% | −94.2% | −45.9% |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
68.30 | 56.70 | 139.51 | 147.14 |
+8 more quarters Free account |
Revenue Growth |
(3.05%) | (76.30%) | (79.07%) | 66.61% | |
Cost of Revenue |
23.49 | 14.25 | 30.70 | 22.10 | |
Gross Profit |
44.81 | 42.45 | 108.82 | 125.04 | |
R&D Expenses |
52.45 | 70.69 | 95.47 | 75.88 | |
SG&A Expenses |
23.65 | 26.67 | 28.78 | 34.12 | |
Operating Income |
(31.28) | (54.91) | (15.43) | 14.23 | |
Non-operating Interest Expenses |
5.40 | 5.69 | 4.90 | 5.82 | |
Non-operating Income/Expense |
1.63 | 3.23 | 6.92 | 3.67 | |
| (29.65) | (51.68) | (8.51) | 17.90 | ||
Income Tax Provision |
1.72 | 1.71 | 0.99 | 0.38 | |
Income after Tax |
(31.38) | (53.39) | (9.49) | 17.53 | |
Dividends (Preferred) |
— | 0.00 | 0.00 | — | |
Net Income Common |
(31.38) | (53.39) | (9.49) | 17.53 | |
EPS (Basic) |
(0.19) | (0.32) | (0.06) | 0.11 | |
EPS (Diluted) |
(0.19) | (0.32) | (0.06) | 0.11 | |
Shares (Basic, Weighted) |
164.92 | 164.57 | 163.28 | 161.99 | |
Shares (Diluted, Weighted) |
164.92 | 164.57 | 163.28 | 173.10 | |
Gross Margin |
65.61% | 74.87% | 78.00% | 84.98% | |
EBIT Margin |
(45.80%) | (96.84%) | (11.06%) | 9.67% | |
EBT margin |
(43.42%) | (91.14%) | (6.10%) | 12.17% | |
Net Profit Margin |
(45.94%) | (94.16%) | (6.80%) | 11.91% | |
EBITDA |
(28.23) | (51.85) | (12.37) | 19.36 | |
EBIT |
(31.28) | (54.91) | (15.43) | 14.23 | |
Income from Continuous Operations |
(31.38) | (53.39) | (9.49) | 17.53 | |
Consolidated Net Income/Loss |
(31.38) | (53.39) | (9.49) | 17.53 | |
EPS (Basic, from Continuous Ops) |
(0.19) | (0.32) | (0.06) | 0.09 | |
EPS (Diluted, from Cont. Ops) |
(0.19) | (0.32) | (0.06) | 0.27 | |
EPS (Basic, Consolidated) |
(0.19) | (0.32) | (0.06) | 0.09 | |
EPS (Diluted, Consolidated) |
(0.19) | (0.32) | (0.06) | 0.27 | |
Shares (Diluted, Average) |
164.92 | 164.57 | 163.28 | 165.18 | |
EBITDA Margin |
(41.34%) | (91.45%) | (8.87%) | 13.15% | |
Operating Cash Flow Margin |
(137.99%) | (128.41%) | (23.24%) | (26.83%) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026